Literature DB >> 11161610

ST14A cells have properties of a medium-size spiny neuron.

M E Ehrlich1, L Conti, M Toselli, L Taglietti, E Fiorillo, V Taglietti, S Ivkovic, B Guinea, A Tranberg, S Sipione, D Rigamonti, E Cattaneo.   

Abstract

The ST14A cell line was previously derived from embryonic day 14 rat striatal primordia by retroviral transduction of the temperature-sensitive SV40 large T antigen. We showed that cell division and expression of nestin persists at 33 degrees C, the permissive temperature, whereas cell division ceases, nestin expression decreases, and MAP2 expression increases at the nonpermissive temperature of 39 degrees C. In this study, we further characterized the cells and found that they express other general and subtype-specific neuronal characteristics. ST14A cells express enolase and beta III-tubulin. Furthermore, they express the striatal marker DARPP-32, which is up-regulated upon differentiation of the cells by growth in serum-free medium. Stimulation with dopamine, the D2-dopamine receptor agonist quinpirole, or the D1-dopamine receptor agonist SKF82958 results in phosphorylation of CREB. Treatment of the cells with a mixture of reagents which stimulate the MAPK and adenylyl cyclase pathways radically changes the morphology of the ST14A cells. The cells develop numerous neurite-like appearing processes which stain with beta III-tubulin. Moreover, under these conditions, intracellular injection of rectangular depolarizing current stimuli elicits overshooting action potentials with a relatively fast depolarization rate when starting from a strongly hyperpolarized membrane potential. Taken together, these data imply that the ST14A cell line displays some of the characteristics of a medium-size spiny neuron subtype and provides a new tool to elucidate the pathways and molecules involved in medium-size spiny neuron differentiation and disease. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161610     DOI: 10.1006/exnr.2000.7551

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  29 in total

1.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

2.  A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease.

Authors:  Kristina Bečanović; Anne Nørremølle; Scott J Neal; Chris Kay; Jennifer A Collins; David Arenillas; Tobias Lilja; Giulia Gaudenzi; Shiana Manoharan; Crystal N Doty; Jessalyn Beck; Nayana Lahiri; Elodie Portales-Casamar; Simon C Warby; Colúm Connolly; Rebecca A G De Souza; Sarah J Tabrizi; Ola Hermanson; Douglas R Langbehn; Michael R Hayden; Wyeth W Wasserman; Blair R Leavitt
Journal:  Nat Neurosci       Date:  2015-05-04       Impact factor: 24.884

3.  Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors.

Authors:  Mohammad A Khanfar; Luisa Quinti; Hua Wang; Johnathan Nobles; Aleksey G Kazantsev; Richard B Silverman
Journal:  ACS Med Chem Lett       Date:  2015-03-26       Impact factor: 4.345

Review 4.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

5.  Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease.

Authors:  Jiun-Tsai Lin; Wei-Cheng Chang; Hui-Mei Chen; Hsing-Lin Lai; Chih-Yeh Chen; Mi-Hua Tao; Yijuang Chern
Journal:  Mol Cell Biol       Date:  2012-12-28       Impact factor: 4.272

6.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

7.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

8.  Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.

Authors:  Luisa Quinti; Vanita Chopra; Dante Rotili; Sergio Valente; Allison Amore; Gianluigi Franci; Sarah Meade; Marta Valenza; Lucia Altucci; Michele M Maxwell; Elena Cattaneo; Steven Hersch; Antonello Mai; Aleksey Kazantsev
Journal:  PLoS Curr       Date:  2010-09-02

9.  The A2A adenosine receptor is a dual coding gene: a novel mechanism of gene usage and signal transduction.

Authors:  Chien-fei Lee; Hsin-Lin Lai; Yi-Chao Lee; Chen-Li Chien; Yijuang Chern
Journal:  J Biol Chem       Date:  2013-11-29       Impact factor: 5.157

10.  Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.

Authors:  Gennady Ermak; Karl J Hench; Kevin T Chang; Sean Sachdev; Kelvin J A Davies
Journal:  J Biol Chem       Date:  2009-03-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.